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Abstract
Lynch syndrome (LS) patients are at high risk of developing colorectal cancer (CRC). Phenotypic variability might in part be 
explained by common susceptibility loci identified in Genome Wide Association Studies (GWAS). Previous studies focused 
mostly on MLH1, MSH2 and MSH6 carriers, with conflicting results. We aimed to determine the role of GWAS SNPs in 
PMS2 mutation carriers. A cohort study was performed in 507 PMS2 carriers (124 CRC cases), genotyped for 24 GWAS 
SNPs, including SNPs at 11q23.1 and 8q23.3. Hazard ratios (HRs) were calculated using a weighted Cox regression analysis 
to correct for ascertainment bias. Discrimination was assessed with a concordance statistic in a bootstrap cross-validation 
procedure. Individual SNPs only had non-significant associations with CRC occurrence with HRs lower than 2, although 
male carriers of allele A at rs1321311 (6p21.31) may have increased risk of CRC (HR = 2.1, 95% CI 1.2–3.0). A polygenic 
risk score (PRS) based on 24 HRs had an HR of 2.6 (95% CI 1.5–4.6) for the highest compared to the lowest quartile, but 
had no discriminative ability (c statistic 0.52). Previously suggested SNPs do not modify CRC risk in PMS2 carriers. Future 
large studies are needed for improved risk stratification among Lynch syndrome patients.
Keywords Lynch syndrome · PMS2 · SNP · Cancer risk · Colorectal cancer · Modifiers
Introduction
Lynch syndrome (LS) accounts for 2–4% of all CRCs and 
is characterized by a high risk for developing malignancies, 
most notably colorectal cancer (CRC) and endometrial 
cancer (EC). The underlying cause is a germline mutation 
in one of the mismatch repair (MMR) genes: MLH1, MSH2 
(EPCAM), MSH6 or PMS2. Mutations in all MMR genes 
are associated with a significantly increased cancer risk 
compared to the general population, although MSH6 and 
PMS2 carriers show lower penetrance compared to MLH1 
and MSH2 carriers [1–3]. Within and between family vari-
ability is commonly observed and a range of theories have Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10689-017-0061-3) contains 
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been proposed to explain the phenomenon, such as geno-
type–phenotype correlations, parent-of-origin effects, life-
style factors and the influence of common susceptibility 
loci. The latter, mainly single nucleotide polymorphisms 
(SNPs), were identified in genome wide association studies 
(GWAS) in large cohorts consisting of sporadic CRC cases 
[4]. Among these candidate SNPs, previous studies have 
identified statistically significant effects of multiple SNPs in 
LS patients, and independent studies replicated the effect of 
SNPs rs3802842 (11q23.1) and rs16892766 (8q23.3) among 
MLH1 carriers [5, 6]. It should be noted, however, that oth-
ers have failed to replicate these findings [7, 8]. Although 
the latter studies analyzed cohorts of similar size to our own, 
few or no PMS2 carriers were included [7]. Due to a rela-
tively low penetrance and high phenotypic variability, this 
specific subset of LS patients might be of particular interest 
[9]. In a previous study among 377 PMS2 carriers, we found 
age at CRC diagnosis to vary widely (range 26–86 years) 
and mean age of index carriers and mutation-positive family 
members differed by 10 years [3]. In the current study, we 
aim to determine whether these SNPs modify CRC risk in a 
large cohort of PMS2 mutation carriers.
Materials and methods
Sample collection
DNA extracted from leucocyte DNA was collected from 8 
Dutch family cancer clinics. Index carriers included in this 
study were sent in between 2007 and 2016 to the Clinical 
Genetics department, because of a clinical suspicion of LS, 
e.g. LS-associated cancer at a young age and/or a positive 
family history. Mutation analysis was initiated based on the 
presence of histological hallmarks [microsatellite instabil-
ity (MSI) or loss of PMS2 expression in the tumor] and/or 
when the family complied with the Bethesda Criteria [10]. 
Participating clinics provided DNA samples and clinical 
data on CRC, age at diagnosis, other cancer development 
and polypectomy. Controls were defined as carriers that were 
tested pre-symptomatically, after a pathogenic mutation was 
identified in the index carrier of the family. All carriers are 
referred to gastroenterology departments after the diagno-
sis has been established, which then adhere to international 
surveillance guidelines, i.e. colonoscopies every 1–2 years 
from 25 years of age [11]. Data was analyzed anonymously. 
The study was approved by the medical ethical committee 
of Leiden University Medical Centre, protocol ID P01-019.
Genotyping
PMS2 genotyping in this cohort was carried out as pre-
viously described [3]. SNP genotyping was done at the 
LUMC laboratory using a KASp genotyping assay (LGC 
Genomics, Hoddesdon, UK). Primers were designed using 
Primerpicker (KBioscience, Hoddesdon, UK) and are avail-
able upon request. All oligonucleotides were obtained from 
Eurofins Genomics (Ebersberg, Germany). Genotypes were 
called using the CFX manager software v3.0 (Bio-Rad, 
Veenendaal, the Netherlands).
Statistical analysis
PMS2 carriers were analyzed as a birth cohort. A Cox-pro-
portional hazards regression model was fitted to estimate 
hazard ratios (HRs), with age at CRC as endpoint and SNP 
genotype as independent variable. Patients without CRC 
were censored at the last age known to be alive. The HR 
was calculated separately for heterozygous and homozygous 
carriers of the risk allele, with homozygotes of the non-
risk allele as reference category. We also calculated the per 
allele HR (additive model). Cox-regression analyses were 
also stratified for gender. These sub-analyses only includes 
a per allele (additive) model, due to multiple testing risks. 
Missing age at CRC diagnosis (n = 3) was imputed using 
median age of CRC in the general population (age 70, n = 2) 
or set at 1 year before death (n = 1). The proportional haz-
ards assumption was investigated by examining the scaled 
Schoenfeld residuals with a formal statistical test and by 
visual inspection.
Previous studies have described the oversampling of cases 
in clinic-based cohorts. Moreover, affected family members 
are more likely to be tested for the mutation and this too 
results in oversampling of cases. To adjust for this non-
random sampling, we used a weighted cohort approach as 
previously described [12]. Standard errors were corrected for 
familial clustering of risk by using the Huber–White sand-
wich estimator [13].
We also calculated two polygenic risk scores (PRS) [14] 
based on (1) the odds ratios (ORs) reported in the meta-
analysis by Ma et al. (Supplemental Table 1) and (2) based 
on our HRs from the current study [4]. Kaplan Meier (KM) 
and Cox regression analysis were concurrently performed. 
A concordance statistic was calculated to assess the dis-
criminative value of the 24 SNP model. The optimism in 
the concordance statistic was estimated by fitting the model 
in each of 500 bootstrap samples (drawn with replacement), 
and validation in the original sample. Analyses were ini-
tially performed for patients with complete data. We also 
performed imputation of missing values based on the cor-
relation structure between SNPs and with the outcome (tran-
scan function in R software, version 3.2). Since results were 
similar, we only present complete case results.
Lastly, a post hoc power analysis was performed to assess 
the chance of finding significantly increased risks using the 
collected cohort, which contains all currently known PMS2 
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mutation carriers in the participating centers (Supplemental 
Fig. 1). We had at least 80% power to find an HR of 1.5 for 
the majority of SNPs. A more detailed description of the 
statistical analysis is available in the supplementary methods 
(Supplemental File 1). Statistical analyses were performed 
using STATA version 14 (StataCorp. 2015. Stata Statistical 
Software: Release 14. College Station, TX: StataCorp LP) 
and R software (version 3.2, using the rms library).
Results
Cohort
In total, 521 samples from carriers with a germline PMS2 
mutation were genotyped, derived from 152 families. Four-
teen patients were excluded because (1) they were younger 
than 25 years at censoring and were therefore not yet at risk 
of developing CRC (n = 11) or (2) insufficient clinical data 
was available (n = 3, including one CRC case). The analyzed 
cohort consisted of 124 cases (PMS2 carriers with CRC) and 
383 controls (PMS2 carriers without CRC), with attributed 
person years of 6527 and 19,549, respectively. Person-years 
were calculated until age of CRC for cases (PMS2 carri-
ers with CRC, n = 125), and age at polypectomy, age of 
death, or last known age alive (whichever occurred first) 
for controls (PMS2 carriers without CRC, n = 1, n = 1 and 
n = 381 respectively). The mean age was 52.5 for CRC cases 
and 51.0 for non-cases (Table 1). For a detailed descrip-
tion of the families including genotypes see Supplemental 
Tables 2a + 2b.
Hardy–Weinberg equilibrium
Two SNPs, rs1048943 (15q24.1) and rs4925386 (20q13), 
were not in Hardy Weinberg equilibrium (HWE). Violation 
of the HWE was present in both cases and controls and as 
this might be the result of a genotyping error, these SNPs 
were removed from the analysis. Ultimately, 24 SNPs were 
included in the final analysis.
Risk of colorectal cancer
None of the SNPs individually showed a clear risk modify-
ing effect (Fig. 1, Supplemental Table 1). There was a dif-
ference in HR between male and female PMS2 carriers for 
Table 1  Cohort description
‘Index carrier’ means the first person to be tested. Incidence of cancer in the group of index carriers with-
out CRC: 20 endometrial cancers, 4 ovarian cancers, 3 breast cancers, 3 cancers of the small intestine, 1 
testis cancer and 1 carcinoid. Ten of these index carriers had not developed any cancer at the time of DNA 
diagnostics; they were tested because of polyps at an early age or because they had an (affected) deceased 
family member
# Lynch syndrome associated cancer
No CRC—controls 
(n = 383)
CRC—cases (n = 124) All (n = 507)
Sex
 Male 133 (34%) 60 (48%) 193 (38%)
 Female 250 (65%) 64 (52%) 314 (62%)
Age (CRC or censoring)
 Mean (s.d.) 51.0 (14.2) 52.5 (12.7)
 Range 25–88 27–88
Index carrier
 Yes 38 (10%) 89 (72%) 127 (25%)
 No, family member 345 (90%) 35 (28%) 380 (75%)
Other cancers (no. of carriers)
 Endometrial  cancer# 30 9 39
 Ovarian# 4 0 4
 Duodenal  cancer# 4 2 6
 Breast# 10 3 13
 Urothelial# 4 2 6
 Esophagus 1 0 1
 Leukemia 0 3 3
 Testis 2 0 2
 Prostate 1 1 2
 Vagina 0 1 1
 Mesothelioma 0 1 1
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Fig. 1  Forest plot of HRs for all SNPs. rs5934683 lies on the X chro-
mosome and was therefore stratified for gender. *SNPs previously 
associated with increased risk in MLH1 mutation carriers. #Reference 
category: homozygous for risk allele (due to low number of homozy-
gous carriers of the non-risk allele). HR Hazard ratio
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rs1321311 (6p21.31), with an HR for the each additional 
A allele of 2.1 (95% CI 1.2–3.0, p = 0.005) and 0.83 (95% 
CI 0.63–1.28, p = 0.56) for males and females, respectively 
(Fig. 2: Forest plot, Supplemental Fig. 2: KM curve).
Combination of rs3802842 and rs16892766
A previous meta-analysis reported a significant pairwise 
effect on CRC risk of rs3802842 (11q23.1) and rs16892766 
(8q23.3) in MLH1 mutation carriers [6]. The HR in the addi-
tive model for this combination in our PMS2 cohort was 0.95 
(95% CI 0.80–1.25, p = 0.99). For carriers of more than three 
risk alleles the HR was 1.58 (95% CI 0.55–3.39) compared 
to patients with no risk alleles, see Fig. 3 for a comparison 
of previously publishes HRs and results from this study. 
The mean age at CRC diagnosis for 0, 1, and more than 1 
risk alleles was 52.8; 52.9 and 50.4 respectively. The cor-
responding median ages were 54 [interquartile range (IQR): 
43–62], 51 (IQR:43–63) and 47 (IQR:39–63). There was a 
statistically non-significant difference between the median 
age of CRC diagnosis between male and female carriers of 
two or more risk alleles, namely 53 (IQR:39–64, n = 7) and 
43.5 years to age (IQR:38–63, n = 10, p = 0.56, Mann–Whit-
ney test).
Fig. 2  Forest plot of HRs for 
rs1321311. p = 0.005 for males. 
HR Hazard ratio
Fig. 3  Forest plot of HRs for 
rs3802842 and rs16892766. 
For the combination of the two 
SNPs, the plotted HR represents 
a comparison for carriers of 
three vs. no risk alleles. HR 
Hazard ratio
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Polygenic risk score
The polygenic risk score was calculated for 444 PMS2 car-
riers with complete genotyping. The medians for PRS1 
(meta-analysis derived ORs) were − 0.12 [interquartile 
range (IQR): − 0.48 to 0.30) for controls and − 0.03 (IQR: 
− 0.39 to 0.40) for CRC cases. The HRs for group 2 (second 
and third quartile) and 3 (fourth quartile) were 1.33 (95% 
CI 0.76–2.33) and 1.50 (95% CI 0.82–2.72) respectively 
(Table 2). The medians for PRS2 (based on HRs from our 
own data) were 0.30 (IQR: − 0.057 to 0.55) for controls and 
0.51 (IQR: 0.068–0.75) for CRC cases. The corresponding 
HRs for group 2 and 3 were 1.05 (95% CI 0.59–1.89) and 
2.62 (95% CI 1.49–4.60) respectively (Table 2). The KM 
curves for PRS1 and 2 are shown in and Supplemental Fig. 3 
and Fig. 4, respectively. The difference between survival 
curves was highly significant for PRS2 (p < 0.0001). The 
optimism-corrected c statistic was only 0.52, indicating no 
discriminatory value.
Discussion
PMS2 carriers currently represent a relatively small propor-
tion of LS patients. However, the number of PMS2-associ-
ated LS cases is expected to rise with the implementation 
of population-based screening protocols for all CRC below 
age 70. Identification of PMS2 carriers has been challenging 
in the past due to difficulties in mutation analysis, a milder 
phenotype and many families not fulfilling clinical selection 
criteria [3, 9, 15–17]. Obtaining a better understanding of 
the specific PMS2-associated phenotype is particularly rel-
evant, as it appears to differ markedly from phenotypes asso-
ciated with other MMR mutations. Unfortunately, we were 
unable to confirm any risk modifying effects of rs3802842 
(11q23.1) and rs16892766 (8q23.1), two SNPs previously 
shown to be associated with enhanced risk in MLH1 muta-
tion carriers [5, 6]. Studies in MLH1 mutation carriers 
reported that a higher number of risk alleles in a carrier is 
associated with a younger onset of disease (28 years younger 
for 3 compared to 0 risk alleles) [6]. In our cohort, mean 
ages where 52.8 and 50.4 for 0 compared to more than 1 risk 
allele, respectively. As such, there seems to be no clinical 
utility of rs3802842 and rs16892766 in risk stratification for 
PMS2 carriers.
Many studies on (genetic) modifiers in LS patients focus 
on MLH1 and MSH2, or MSH6 carriers, while PMS2 is 
seldom analyzed. The only study to include PMS2 carriers 
(n = 40) found that carriers of the G-alleles of rs10795668 
Table 2  Polygenic risk scores
PRS polygenic risk score, IQR interquartile range
PRS1 Weighted on odds ratios from general population, i.e. in sporadic CRC cases
PRS2 Weighted on hazard ratios from this study
Log rank survival curves PRS1: p = 0.32
Log rank survival curves PRS2: p < 0.0001
PRS category Controls CRC Expected 
events
HR p for HR
PRS1 Median (IQR) − 0.12 (− 0.48 to 0.30) − 0.03 (− 0.39 to 0.40)
First quartile 84 22 28 Ref 0.41
Second and third quartile 167 54 52 1.33 (0.76–2.33) 0.31
Fourth quartile 84 33 28 1.50 (0.82–2.72) 0.19
PRS2 Median (IQR) 0.30 (− 0.057 to 0.55) 0.51 (0.068–0.75)
First quartile 84 18 26 Ref < 0.0001
Second and third quartile 165 38 53 1.05 (0.59–1.89) 0.86
Fourth quartile 84 53 30 2.62 (1.49–4.60) 0.001
Fig. 4  Kaplan Meier survival curve for PRS2. This plot compares 
curves for the lowest, the two middle and the highest quartile of the 
PRS. PRS2 is based on hazard ratios from the current study. HR Haz-
ard ratio, PRS polygenic risk score
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(10p14) and rs9929218 (16q22.1) were at lower risk of CRC, 
a notable finding in that this is the opposite effect compared 
to sporadic CRC [7]. The authors conceded that their results 
should be confirmed in larger studies. As these findings have 
not been confirmed in our much larger cohort, we suggest 
that these previous findings may indeed have been false posi-
tives due to the small number of carriers included.
A relevant question is why our study did not confirm 
reported findings of previous studies of MMR carriers. 
One explanation might be that although patients have ger-
mline mutations in genes with similar functions, carriers 
are affected by genetic modifiers in different ways. Indeed, 
comparable studies in BRCA1 or BRCA2 mutation carri-
ers have resulted in the identification of SNPs that clearly 
modify breast cancer risk. However, BRCA2 carriers appear 
unaffected by SNPs that confer an increased breast cancer 
risk in BRCA1 carriers, even though both genes play a role 
in homologous recombination [18]. This could also hold for 
MMR mutation carriers, as illustrated by the observation 
that while rs3802842 and rs16892766 may increase risk in 
MLH1 carriers, they do not appear to have an effect in MSH2 
or PMS2 carriers [5, 6]. Researchers should therefore con-
centrate on building cohorts large enough to analyze Lynch 
patients in a gene-stratified manner.
Gender stratification in our cohort led to the notable 
finding that male carriers of allele A at locus rs1321311 
(6p21.31) show a per allele HR of 2.07 (95% CI 1.21–2.96), 
while the HR for females was 0.83 (95% CI 0.63–1.28). This 
SNP has been linked to the CDKN1A gene that encodes the 
p21 protein. p21 is involved in several (p53-independent) 
pathways as a tumor suppressor, although it also has onco-
genic characteristics [19, 20]. Interestingly, down-regulation 
of p21 is inversely associated with MSI, the hallmark of 
Lynch-associated tumors. One study found that a larger pro-
portion of Lynch-associated CRCs expressed p21 compared 
to sporadic CRCs (80 vs. 31%) [21]. However, a recent study 
reported on expressive Quantitative Trait Loci (eQTL) in 
colonic tissue based on data from the GTEx project portal 
(http://www.gtexportal.org/home/) and did not find a statisti-
cally significant effect of rs1321311 on CDKN1A expres-
sion in sigmoid and transverse colon tissue (p = 0.84 and 
p = 1.00 respectively) [22, 23]. It is also unclear why this 
effect only appears to be present in male PMS2 carriers. 
Although no gender difference was noted by the meta-anal-
ysis that identified the SNP [19], it is possible that gender 
differences exist, as CRC risk in the general population and 
in Lynch patients is known to be higher in men compared 
to women [24, 25]. Indeed, mutations are more often found 
in males than females when assessed for Lynch syndrome 
[26]. Another possible explanation for this gender specific 
effect might lie in the effect of other risk modifiers. It is per-
ceivable that other factors than SNPs have a stronger influ-
ence on (colorectal) cancer development in women, such as 
hormonal factors [27, 28]. Unfortunately data on hormone 
levels or other factors previously shown to modify cancer 
risk in LS such as medication use (e.g. aspirin) or environ-
mental factors were unavailable for analysis and as such we 
were unable to correct for this [29–33]. Similarly, data on 
smoking and BMI were only available for a small proportion 
of carriers (n = 131, 26%). It should be emphasized that all 
results after gender stratification should be interpreted with 
caution because of small sample size and multiple testing. 
This could have led to false associations. Further studies are 
needed to validate these findings.
We also investigated the effect of the 24 SNPs on CRC 
risk in the PMS2 cohort by means of a polygenic risk score 
(PRS). While there did not appear to be a significant effect 
of the PRS based on ORs from sporadic CRC cohorts, there 
was a difference in the cumulative incidence of CRC for 
PMS2 carriers with a PRS2 (based on HRs in this study) in 
the highest quartile. Bootstrap validation however refuted 
this promising observation. Further studies are hence needed 
in other large cohorts.
There were some limitations to this study. Our study con-
sisted exclusively of Dutch PMS2 carriers and thus had a 
relatively homogeneous genetic makeup, implying that dif-
ferences between our results and previous studies might be 
due to population-specific effects.
A second limitation might be that we did not correct for 
the specific mutation present in each family, mainly because 
in the majority of families the segregating PMS2 mutation is 
rare or even unique. A previous study by our group did not 
identify such a correlation with CRC risk in PMS2 carriers 
(Supplemental Tables 2a + 2b Table: for more details) [34].
Unfortunately, we were not able to validate our findings 
in an external cohort. To our best knowledge this is one of 
the largest PMS2 cohorts currently collected, and bootstrap 
validation is a strong approach to assess discriminative abil-
ity of a prediction model [35]. Stratifying our cohort into a 
discovery and validation cohort was not a viable option as 
this would have resulted in a substantial decrease in power. 
Our study might already have been underpowered to detect 
weak associations. However, while such associations are 
interesting from a scientific point of view and may be rel-
evant to tumorigenesis, they are not necessarily useful in 
clinical practice when the effect is small. For the two SNPs 
previously found to increase risk in MLH1 mutation carri-
ers, we had 60–80% power to detect an HR of 1.5, which we 
would consider clinically relevant. The previously reported 
HR in MLH1 carriers for rs3802842 was 2.7, an HR for 
which we have ample power to detect (Supplemental Fig. 1).
Families with a segregating PMS2 mutation show a 
high degree of phenotypic variability. We were not able to 
confirm the risk modifying effect of rs3802842 (11q23.1) 
and s16892766 (8q23.3), which were previously found to 
increase the risk in MLH1-associated LS. This, together 
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with the established lower penetrance, raises the question 
of whether PMS2-associated LS should be considered a 
separate Lynch disease entity. Additional explanations 
for phenotypic variability that warrant greater exploration 
include gene-environment interactions and risk modification 
by other genetic variants.
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